🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

AstraZeneca's Beyfortus gets approval in Japan for RSV prevention

EditorEmilio Ghigini
Published 03/27/2024, 09:24 AM
© Reuters
AZN
-

TOKYO - AstraZeneca (NASDAQ:AZN), in partnership with Sanofi (NASDAQ:SNY), has announced that its long-acting monoclonal antibody, Beyfortus (nirsevimab), has received approval from the Japanese Ministry of Health, Labour and Welfare for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in a broad infant population.

Beyfortus is now authorized for prophylaxis in all neonates and infants entering their first RSV season and for those at risk of serious RSV infection entering their first or second season.

The newly approved treatment is the first to offer RSV disease prevention for such a wide range of infants, including those born at term, preterm, or with certain health conditions that increase vulnerability to severe disease. Beyfortus is expected to be available for the 2024/25 RSV season, aligning with Japanese health guidelines.

The approval is supported by evidence from three pivotal late-stage clinical trials, which demonstrated that a single dose of Beyfortus provided consistent protection against RSV LRTD over a five-month period, typically covering the duration of an RSV season. In Japan, over 100,000 cases of RSV LRTD are reported annually among infants, including those born healthy and at term.

Dr. Hiroyuki Moriuchi, a leading pediatrician at Nagasaki University, hailed the approval as a significant step in combating RSV in infants, a common and burdensome illness that can lead to long-term health issues. Iskra Reic, Executive Vice President at AstraZeneca, emphasized the potential of Beyfortus to alleviate the healthcare burden by preventing serious respiratory diseases in all infants in Japan.

Beyfortus has previously been approved in the European Union, United States, and China. This approval marks a continuation of AstraZeneca's commitment to developing preventive healthcare solutions for vulnerable patient groups.

The approval criteria for Beyfortus in Japan cover neonates, infants, and children at risk of severe RSV infection, including those born prematurely or with specific health conditions such as chronic lung disease, significant congenital heart disease, immunocompromised conditions, or Down syndrome.

AstraZeneca and Sanofi will co-promote Beyfortus in Japan, reflecting the companies' collaborative efforts in the development and commercialization of the treatment. This announcement is based on a press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.